Oct 07, 2019
Spinraza access agreement extended in England
More children with the rare genetic disorder spinal muscular atrophy (SMA) can now be treated with Spinraza after NICE published on July 3, 2019, amended draft guidance following a proposal for extending the terms of the managed access agreement between NHS England and Biogen for funding it.

The company made the proposal taking into consideration further clinical evidence. The managed access agreement has also been refined in light of a number of requests for clarification.

The most significant change to the managed access agreement is that it will now include pediatric patients who have recently (in the previous 12 months) lost the ability to walk independently. This replaces the prior criteria that patients, who had previously gained ambulation, should still be able to walk independently at the start of their treatment with Spinraza.

It is estimated there are between 600 and 1200 children and adults in the UK living with SMA.

See full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)